| Autor: |
Shuangzhe Zhang, Chunhui Gao, Tuhin Das, Shuhong Luo, Hao Tang, Xinyi Yao, Chih Yun Cho, Jingqiao Lv, Kino Maravillas, Valerie Jones, Xiaofeng Chen, Ruopan Huang |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of immunological methods. 503 |
| ISSN: |
1872-7905 |
| Popis: |
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has become a worldwide pandemic, and there is a pressing need for the rapid development of novel therapeutic strategies. SARS-CoV-2 viral entry is mediated by interaction between the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein and host cellular receptor, human angiotensin converting enzyme 2 (ACE2). The lack of a high throughput screening (HTS) platform for candidate drug screening means that no targeted COVID-19 treatments have been developed to date. To overcome this limitation, we developed a novel, rapid, simple, and HTS binding assay platform to screen potential inhibitors of the RBD-ACE2 complex. Three "neutralizing" mouse monoclonal antibodies capable of blocking the RBD-ACE2 interaction were identified using our binding assay and pseudovirus neutralization assay followed by further validation with the Focus Reduction Neutralization Test (FRNT), which analyzes the neutralization capacity of samples in the presence of live SARS-CoV-2. Furthermore, the consistency of our binding assay and FRNT results (R |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect